Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666780 | 0.89 | MEN1 (0.47) | OPRM1OPRL1OPRK1MEN1CYP2C9 | |
| SCHEMBL1944655 | 0.83 | MEN1 (0.45) | OPRM1OPRK1MEN1CYP2C9KMT2A | |
| SCHEMBL15656775 | 0.82 | HDAC4 (0.44) | MEN1CYP2C9KMT2AAKR1C1SIGMAR1 | |
| SCHEMBL15659683 | 0.82 | HDAC4 (0.44) | MEN1CYP2C9KMT2AAKR1C1SIGMAR1 | |
| SCHEMBL10042118 | 0.82 | AKR1B1 (0.38) | OPRM1OPRK1CYP2C9AKR1B1LMNA | |
| SCHEMBL12893199 | 0.78 | OPRM1 (0.50) | OPRM1OPRL1KMT2AALDH1A1 | |
| SCHEMBL1631912 | 0.77 | HDAC4 (0.41) | OPRM1OPRK1CYP2C9ALDH1A1LMNA | |
| SCHEMBL11489569 | 0.77 | MEN1 (0.50) | OPRM1OPRL1OPRK1MEN1CYP2C9 | |
| SCHEMBL1629725 | 0.76 | HDAC4 (0.40) | OPRM1OPRK1CYP2C9ALDH1A1LMNA | |
| SCHEMBL29883511 | 0.75 | MEN1 (0.48) | OPRM1OPRL1OPRK1MEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131510-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESRRB, ESR2, ESRRA | OPRM1 103/4885OPRL1 60/4885OPRK1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.